NDASUBCUTANEOUSSOLUTION1 Generic Approved
Approved
Jan 2010
Lifecycle
Peak
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
5/8 — Partial
VICTOZA (liraglutide) by Novo Nordisk is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2010.
Drug data last refreshed 48m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VICTOZA (liraglutide) is a GLP-1 receptor agonist indicated for type 2 diabetes management. It works by mimicking glucagon-like peptide-1, stimulating insulin secretion and reducing glucagon in response to blood glucose levels. Administered via subcutaneous injection, it helps improve glycemic control in adult patients with type 2 diabetes.
Peak10.8 years to LOE
VICTOZA remains in peak commercial phase despite intense GLP-1 competition; teams are focused on managed care positioning and maintaining market share against newer entrants.
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
GLP-1 Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Started Nov 2025
71 enrolled
Obesity
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
Started Jul 2022
0Diabetes Mellitus, Type 2
Efficacy of Liraglutide Therapy in Patients With IPAA
Started Mar 2022
8 enrolled
PouchitisIrritable Pouch Syndrome
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity
Started Nov 2021
206 enrolled
Obesity
Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
Started Jun 2021
34 enrolled
ObesityStatus Post Sleeve Gastrectomy
Worked on VICTOZA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.